OptiBiotix Health PLC Launch of LeanBiome in Muscletech (5934Z)
15 Gennaio 2024 - 8:00AM
UK Regulatory
TIDMOPTI
RNS Number : 5934Z
OptiBiotix Health PLC
15 January 2024
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Launch of LeanBiome(R) in Muscletech(R)
OptiBiotix Health plc (AIM: OPTI), a life sciences busi ness d e
vel o ping co m p o u n ds to tack le o besit y, high choleste r
ol, diabetes and skincare announces the forthcoming launch of
LeanBiome(R) in Muscletech(R), one of the leading sports nutrition
brands in the industry and backed by America's No. 1 selling sports
supplement company (see About Us -- MuscleTech ). The product is
currently being advertised on social media by the Company's partner
ahead of online and instore launches with multiple retailers in
Sweden, France, Poland, Germany, the Netherlands, Greece and the UK
- see
https://www.stack3d.com/2024/01/muscletech-nitro-tech-ripped-europe.html
Muscletech (R) is known as a leading brand in the science
nutrition space recognised for its research with scientific experts
to identify and utilise science backed ingredients in their
products to bring unique benefits to athletes and fitness
enthusiasts around the world. LeanBiome(R) will be incorporated in
Muscletech Nitro Tech Ripped range, a premium protein powder
designed to support athletes who want to lose fat and build lean
muscle and will be launched in Europe and the United Kingdom across
multiple e-commerce sites and distribution channels.
LeanBiome(R) is a scientifically formulated sports nutrition
ingredient which has been developed by OptiBiotix to support
athletes seeking to increase lean muscle mass and to change their
body composition. LeanBiome(R) contains a patented combination of
fibres, prebiotics and minerals developed to increase the
microbiome diversity of athletes on a high protein diet. A diverse
microbiome is important in harvesting essential nutrients from the
diet and has been linked to improved health and wellbeing and
increased resilience to disease. Many researchers now believe that
a diverse microbiome is an essential factor in achieving physical
fitness, which was previously thought to be achievable solely
through a healthy diet and regular exercise. This is supported by
the growing scientific evidence of a link between the microbiome
and athletic performance which suggest that optimizing an athletes
gut microbiome could improve and athletes stamina, lower
inflammation, and support physical fitness ( Frontiers | Editorial:
Nutrition to support gut health and the microbiome in athletes
(frontiersin.org)
Stephen OHara, C EO of O pti B i oti x Health plc c o mmented :
"We are very pleased to announce the launch of LeanBiome (R) with
such a well-known and internationally respected sports brand such
as Muscletech (R) . LeanBiome(R) has been formulated to support
anyone interested in improving their fitness for leisure or the
elite athlete. It is supported by multiple published clinical
studies which show it helps reduce body fat around the waist and
hips, improving body leanness whilst enhancing the diversity of the
gut microbiome to improve stamina and overall fitness.
"LeanBiome(R) is a unique product which is increasingly being
recognised by major sports brands as a key differentiator from
existing products and has the potential to have a major impact in
the sports nutrition and health and fitness markets ."
This announcement contains information which, prior to its
disclosure, was considered inside information for the purposes of
the UK Market Abuse Regulation and the Directors of the Company are
responsible for the release of this announcement.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman Contact via Walbrook below
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Peterhouse Capital Limited (Broker) Tel: 020 7220 9797
Duncan Vasey / Lucy Williams
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBTMFTMTJBBBI
(END) Dow Jones Newswires
January 15, 2024 02:00 ET (07:00 GMT)
Grafico Azioni OptiBiotix Health (AQSE:OPTI.GB)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni OptiBiotix Health (AQSE:OPTI.GB)
Storico
Da Dic 2023 a Dic 2024
